ArticleMedicine and pharmacy reports2026
Post-COVID-19: effects on mental health and metabolic markers in type 2 diabetes.
Article in Medicine and pharmacy reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to assess the impact of COVID-19 infection on both mental well-being and biological parameters of patients with type 2 diabetes, highlighting the potential long-term effects. Methods: A longitudinal observational study was conducted on a total of 62 patients diagnosed with type 2 diabetes. We used two validated questionnaires: the WHO-5 Well-Being Index (WHO-5) and the Diabetes Distress Scale (DDS). Biological data were extracted from medical records. We had two-point evaluations, in 2023 and 2024. Patients were divided into three groups based on the year of COVID-19 diagnosis: 2020, 2021, 2022. Descriptive and inferential statistics were performed, with results presented as percentages and associations. The Wilcoxon signed-rank test, the Kruskal-Wali's test, and Spearman's rank correlation coefficient (ρ) were applied for non-normally distributed variables. Analyses were performed using Jamovi 3.2.28. A p value < 0.05 was considered statistically significant. Results: There were 24 (38.7%) females, and 38 (61.3%) males. The mean age was 66.5 years. From the medical history, regarding COVID-19 severity, 7 (11.3%) of cases were classified as mild 29 (46.8%) as moderate, and 26 (41.9%) as severe. WHO-5 scores increased from a mean of 42.5 from 2023 to 51.2 in 2024, indicating improved psychological well-being over time. A significant reduction in diabetes-related emotional distress was observed (p < 0.001). Regimen-related distress scores showed a small but significant decrease from 2023 to 2024 (p = 0.004). A statistically significant correlation was observed between WHO-5 score (2023) and LDL cholesterol (2024) (ρ = 0.629, p = 0.02). Descriptive statistics showed that mean HDL cholesterol values vary with COVID-19 severity levels. Conclusion: Psychological well-being showed an improvement over time. Emotional distress related to diabetes, including emotional burden and regimen-related distress decreased with time. Serum LDL- and HDL cholesterol levels may play a potential role in supporting psychological well-being. This study reinforces the importance of holistic approaches in managing post-COVID-19 effects, especially in patients with pre-existing metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.